Back to Report Store Home

Epilepsy Therapeutics in Asia-Pacific Markets to 2024 – Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth

  • Published: Nov-2018
  • Report Code: GBIHC484MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Disease Classification 11

2.4 Symptoms 13

2.5 Etiology and Pathophysiology 14

2.5.1 Etiology 14

2.5.2 Pathophysiology 15

2.6 Diagnosis 17

2.6.1 Biomarkers 19

2.7 Prognosis 20

2.8 Treatment Guidelines and Options 21

2.8.1 Treatment Options 21

3 Marketed Products 28

3.1 Overview 28

3.1.1 Aptiom/Zebinix (Eslicarbazepine acetate) – BIAL-Portela 29

3.1.2 Banzel/Inovelon (Rufinamide) – Novartis 30

3.1.3 Briviact (Brivaracetam) – UCB 31

3.1.4 Fycompa (perampanel) – Eisai 32

3.1.5 Keppra (levetiracetam) – UCB 34

3.1.6 Lyrica (pregabalin) – Pfizer 36

3.1.7 Vimpat (lacosamide) – UCB 37

3.1.8 Lamictal (lamotrigine) – GSK 39

3.1.9 Epidiolex (Cannabidiol) - GW Pharmaceuticals 40

3.1.10 Older Generation AEDs 41

3.2 Comparative Efficacy and Safety of Marketed Product 42

4 Pipeline Analysis 44

4.1 Overview 44

4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 44

4.3 Pipeline Distribution by Molecular Target 45

4.4 Promising Pipeline Candidates 48

4.4.1 Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) – Zogenix 48

4.4.2 Cenobamate (YKP3089) – SK Biopharmaceuticals 50

4.5 Comparative Efficacy and Safety of Pipeline Products 52

4.6 Product Competitiveness Framework 53

5 Clinical Trial Analysis 54

5.1 Failure Rate 54

5.1.1 Overall Failure Rate 54

5.1.2 Failure Rate by Phase and Molecule Type 55

5.1.3 Failure Rate by Phase and Molecular Target 55

5.2 Clinical Trial Size 56

5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 56

5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 57

5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 58

5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 59

5.3 Clinical Trial Duration 60

5.3.1 Clinical Trial Duration by Molecule Type 60

5.3.2 Clinical Trial Duration by Molecular Target 61

5.4 Competitive Clinical Trials Metrics Analysis 62

6 Multi-scenario Forecast 64

6.1 Geographical Markets 64

6.2 Asia-Pacific Market 65

6.3 India 66

6.3.1 Treatment Usage Patterns 66

6.3.2 Annual Cost of Therapy 68

6.3.3 Market Size 69

6.4 China 70

6.4.1 Treatment Usage Patterns 70

6.4.2 Annual Cost of Therapy 71

6.4.3 Market Size 72

6.5 Australia 73

6.5.1 Treatment Usage Patterns 73

6.5.2 Annual Cost of Therapy 74

6.5.3 Market Size 75

6.6 South Korea 76

6.6.1 Treatment Usage Patterns 76

6.6.2 Annual Cost of Therapy 77

6.6.3 Market Size 78

6.7 Japan 79

6.7.1 Treatment Usage Patterns 79

6.7.2 Annual Cost of Therapy 80

6.7.3 Market Size 82

7 Drivers and Barriers 83

7.1 Drivers 83

7.1.1 Improved Economy and Affordability Boost the Market 83

7.1.2 Promising Pipeline Products that Target Unmet Needs for Epilepsy 83

7.1.3 Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment 83

7.2 Barriers 84

7.2.1 Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates 84

7.2.2 Impending Patent Cliffs and Generic Erosion 84

7.2.3 Lack of Strong Patent Protection or Intellectual Property Rights. 84

8 Deals and Strategic Consolidations 85

8.1 Licensing Deals 85

8.1.1 Deals by Region and Value 85

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 86

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87

8.2 Key Licensing Deals 90

8.3 Co-development Deals 91

8.3.1 Deals by Region and Value 91

8.3.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92

8.3.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 93

8.4 Key Co-development Deals 96

9 Appendix 98

9.1 All Pipeline Drugs by Stage of Development 98

9.1.1 Discovery 98

9.1.2 Preclinical 99

9.1.3 IND/CTA-filed 103

9.1.4 Phase I 103

9.1.5 Phase II 104

9.1.6 Phase III 105

9.1.7 Pre-registration 106

9.2 Summary of Multi-scenario Market Forecasts to 2024 107

9.2.1 Asia-Pacific 107

9.2.2 India 107

9.2.3 China 107

9.2.4 Australia 108

9.2.5 South Korea 108

9.2.6 Japan 109

9.3 Bibliography 109

9.4 Abbreviations 114

9.5 Research Methodology 116

9.5.1 Secondary Research 117

9.5.2 Marketed Product Profiles 117

9.5.3 Late-Stage Pipeline Candidates 117

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 117

9.5.5 Product Competitiveness Framework 118

9.5.6 Pipeline Analysis 118

9.5.7 Forecasting Model 119

9.5.8 Deals Data Analysis 119

9.6 Contact Us 120

9.7 Disclaimer 120

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards